logo-loader
viewNemaura Medical Inc

Nemaura Medical CEO Faz Chowdhury to give insights into sugarBEAT study in new interview

The medical technology company is the thick of commercializing sugarBEAT, a non-invasive and flexible continuous glucose monitor for diabetes management

Nemaura Medical Inc -
The interview will air on RedChip Companies' YouTube channel on May 11

Nemaura Medical Inc (NASDAQ:NMRD) CEO Dr Faz Chowdhury will give investors new insights into its sugarBEAT study in an interview with RedChip Companies on May 11.

The medical technology company is in the midst of commercializing sugarBEAT, a non-invasive and flexible continuous glucose monitor (CGM) for diabetes management.

In a statement, the Loughborough, England-based company said its CEO will provide insights into its head-to-head study with a major existing glucose monitoring solution with the goal of positioning sugarBEAT as an alternative to expensive and invasive continuous glucose monitors.

READ: Nemaura preparing for launch of sugarBEAT glucose monitor in the US

Nemaura has several studies planned over the course of this year designed to demonstrate the effectiveness of sugarBEAT to increase Time-In-Range, thus reducing Hemoglobin A1C with intermittent use over a few non-consecutive days per week or month.

Initial results from studies comparing the various market-leading CGM devices indicates sugarBEAT’s accuracy is on par with the major incumbent invasive CGM sensors, using single finger-stick blood glucose meter calibration in real-life settings, according to Nemaura.

CGMs are big business internationally, with the global total addressable market for CGMs estimated at $82 billion per year. The figure consists of $12.7 billion for Type 1 insulin users, $38 billion for Type 2 insulin users and $31.4 billion for Type 2 non-insulin users, which make up 80% of people with diabetes. The numbers exclude the prediabetes population which is estimated to be nearly three times as large as the diabetes population, according to data provided by Nemaura.

The firm is prioritizing launch plans in the US and is considering various options to expedite the launch, including possibly partnering with multinational companies.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Nemaura Medical Inc

Price: 7.76 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $162.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read